The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases.
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report / De Benedittis, Caterina; Papayannidis, Cristina; Venturi, Claudia; Maria Chiara, Abbenante; Paolini, Stefania; Parisi, Sarah; Sartor, Chiara; Cavo, Michele; Martinelli, Giovanni; Soverini, Simona. - In: BMC CANCER. - ISSN 1471-2407. - ELETTRONICO. - 17:1(2017), pp. 523.1-523.8. [10.1186/s12885-017-3511-2]
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
De Benedittis, Caterina;Papayannidis, Cristina;Venturi, Claudia;Abbenante, Maria Chiara;Paolini, Stefania;Parisi, Sarah;Sartor, Chiara;Cavo, Michele;Martinelli, Giovanni;Soverini, Simona
2017
Abstract
The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases.File | Dimensione | Formato | |
---|---|---|---|
12885_2017_Article_3511.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
688.99 kB
Formato
Adobe PDF
|
688.99 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.